Relacorilant + Nab-Paclitaxel for Ovarian Cancer
Trial Summary
What is the purpose of this trial?
This trial tests a new combination of two drugs for ovarian cancer patients who have no other treatment options left. The combination includes a drug that may make chemotherapy more effective and a chemotherapy drug that has been used in various cancer treatments. The goal is to see if this combination can help patients live longer without their disease getting worse.
Research Team
Sachin Pai, MD
Principal Investigator
Corcept Therapeutics
Eligibility Criteria
This trial is for patients with advanced, platinum-resistant high-grade ovarian, primary peritoneal, or fallopian tube cancer. Participants must have had 1-3 prior cancer treatments including platinum therapy and bevacizumab. They should not have unresolved severe side effects from past treatments, no major surgery within the last month, and no untreated brain metastases.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- Nab-paclitaxel (Anti-tumor antibiotic)
- Relacorilant (Corticosteroid)
Nab-paclitaxel is already approved in Canada for the following indications:
- Metastatic breast cancer
- Non-small cell lung cancer
- Adenocarcinoma of the pancreas
Find a Clinic Near You
Who Is Running the Clinical Trial?
Corcept Therapeutics
Lead Sponsor
Dr. Joseph K. Belanoff
Corcept Therapeutics
Chief Executive Officer since 2014
MD from Stanford University
Dr. William Guyer
Corcept Therapeutics
Chief Medical Officer since 2021
PharmD
Gynecologic Oncology Group
Collaborator